Loading
Life sciences · Journal article
Cancer · September 28, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
ABSTRACT Background Progression‐free survival (PFS) is a common primary endpoint in first‐line epithelial ovarian cancer (EOC) trials; however, its relationship with overall survival (OS) remains uncertain. The patient‐level PFS‐OS association among individuals with BRCA wild‐type advanced EOC treated with first‐line platinum‐based chemotherapy was evaluated. Methods This retrospective analysis pooled patient‐level data from first‐line advanced EOC historical trials sourced from the Medidata Enterprise Data Store. Eligible patients had BRCA wild‐type disease and initiated platinum‐based chemotherapy (index date) after primary debulking surgery or as neoadjuvant therapy before planned interval debulking surgery. The PFS‐OS association was evaluated using Spearman's correlation (ρ) and landmark analyses at prespecified timepoints (9, 12, 15, and 18 months after index). Results Among 487 patients (50.1% aged ≥65 years; 90.1% White; 63.7% International Federation of Gynecology and Obstetrics stage III; 54.6% ECOG‐PS 0; 37.3% primary debulking surgery; 53.0% interval debulking surgery; median follow‐up 3.4 years), the median PFS and OS were 15.6 months (95% CI, 13.8–16.8) and 42.1 months (95% CI, 37.8–45.7), respectively. The PFS‐OS correlation (ρ) was 0.7 (95% CI, 0.6–0.8). Across all landmarks, progression‐free patients experienced longer subsequent OS; at 15 months, the unadjusted HR was 0.29 (95% CI, 0.22–0.37). Associations remained after covariate adjustment and did not vary by best overall response, bevacizumab use, or surgical type/outcomes. Conclusion In this patient population, PFS demonstrated a consistently moderate, positive association with OS across multiple analytical approaches. These findings provide patient‐level evidence that PFS is an informative early endpoint, although additional trial‐level evaluations are needed to confirm PFS as a validated surrogate for OS in first‐line EOC.